Does levetiracetam (Keppra) worsen schizophrenia?

Levetiracetam Can Worsen Pre-existing Schizophrenia But May Also Improve Certain Symptoms in Specific Contexts

The FDA label explicitly documents one case of "worsening of pre-existent schizophrenia" in a patient taking Keppra, though this did not lead to drug discontinuation 1. This represents the highest-quality evidence directly addressing your question, as it comes from the official drug labeling based on clinical trial data.

The Paradox: Risk vs. Potential Benefit

The relationship between levetiracetam and schizophrenia is complex and bidirectional:

Risk of Worsening (FDA-Documented)

The FDA label clearly states that in long-term studies examining patients with primary generalized epilepsy, 2 of 192 patients exhibited psychotic-like behavior 1. One case involved auditory hallucinations and suicidal thoughts (leading to discontinuation), while the other was specifically described as "worsening of pre-existent schizophrenia" that did not require discontinuation 1.

Additionally, levetiracetam causes:

• Psychotic symptoms in 0.7% of treated patients (vs 0.2% placebo) 1
• Delusional behavior requiring dose reduction 1
• Behavioral and mood disorders in 11.4-13.3% of patients 1

Potential for Improvement (Research Evidence)

Paradoxically, recent high-quality research suggests levetiracetam may improve certain schizophrenia symptoms:

• A 2022 randomized controlled trial showed levetiracetam significantly reduced all PANSS subscales, especially negative symptoms, and improved cognitive function in chronic schizophrenia patients 2
• A 2023 preclinical study demonstrated that levetiracetam attenuated stress-induced behavioral changes associated with schizophrenia 3
• A 2017 case report described complete symptom resolution in a patient with schizophrenia-like symptoms and epileptiform discharges treated with levetiracetam 4

Clinical Decision Algorithm

For patients WITH pre-existing schizophrenia requiring seizure treatment:

1. Avoid levetiracetam as first-line due to FDA-documented risk of worsening pre-existing schizophrenia 1
2. If levetiracetam must be used (e.g., other antiepileptics failed):
   • Start at lowest effective dose
   • Monitor closely for psychotic symptom exacerbation (weekly for first month)
   • Ensure stable antipsychotic regimen is in place
   • Have immediate plan for dose reduction or discontinuation

For patients WITHOUT schizophrenia:

1. Screen for psychiatric history before initiating levetiracetam
2. Risk factors for psychiatric adverse effects include:
   • Prior psychiatric illness
   • Male sex
   • Age <60 years
   • Poorly controlled epilepsy 5
3. If psychotic symptoms emerge (0.7% risk):
   • Reduce dose or discontinue immediately 1
   • Most symptoms resolve within 1-2 weeks of discontinuation 1

Critical Caveats

The research showing benefit in schizophrenia patients 2, 4 appears to contradict the FDA warning 1. This discrepancy likely reflects:

• Different patient populations (epileptiform activity vs. pure schizophrenia)
• The 2022 RCT used levetiracetam as an adjunct to antipsychotics, not monotherapy 2
• The beneficial cases may represent a specific subgroup with hippocampal hyperactivity or epileptiform discharges 4

The FDA label takes precedence for clinical decision-making because it represents regulatory-grade evidence from large-scale trials, and explicitly documents worsening of pre-existing schizophrenia 1.

Monitoring Requirements

If levetiracetam is used despite schizophrenia:

• Weekly psychiatric assessment for first 4 weeks (when symptoms most commonly emerge) 1
• Monitor for: hallucinations, delusions, aggressive behavior, agitation, suicidal ideation 1, 6
• Have antipsychotic medication readily available for acute management 5
• Discontinuation rate due to psychiatric effects: 2.4-3.4% 5

Bottom line: The FDA-documented case of worsening pre-existing schizophrenia makes levetiracetam a poor choice for patients with established schizophrenia unless no alternatives exist 1. The emerging research suggesting benefit applies to highly selected patients and should not override this safety concern in routine practice.